| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Emzeltrectinib is a potent tyrosine kinase inhibitor (TKI) with antineoplastic activity, though its specific target(s) are not detailed in the provided references. It is classified under the c-MET product category, suggesting it may inhibit c-MET or related receptor tyrosine kinases.
|
|---|---|
| ln Vitro |
A typical in vitro kinase inhibition assay is performed using a panel of recombinant receptor tyrosine kinases (e.g., c-MET, VEGFR, EGFR). Increasing concentrations of Emzeltrectinib are incubated with each kinase and ATP. A peptide substrate is added, and phosphorylation is measured via time-resolved fluorescence resonance energy transfer (TR-FRET) or ADP-Glo detection to determine IC50 values.
|
| ln Vivo |
Dedicated in vivo studies for Emzeltrectinib are not detailed. As a potent TKI with antineoplastic activity, it is expected to show tumor growth inhibition in appropriate xenograft mouse models of cancers driven by its target kinases.
|
| Animal Protocol |
No detailed in vivo animal experiment data is available for Emzeltrectinib.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is reported for Emzeltrectinib. As a potent TKI, it is expected to be evaluated for oral bioavailability and half-life in preclinical studies.
|
| Toxicity/Toxicokinetics |
No specific toxicology data is reported for Emzeltrectinib, as it is currently a preclinical research compound.
|
| References | |
| Additional Infomation |
Emzeltrectinib is a small molecule drug. The International Nonproprietary Name (INN) prefix "-trectinib" in its name indicates that Emzeltrectinib is a tropomyosin receptor kinase (TRK) inhibitor. The monoisotopic molecular weight of Emzeltrectinib is 376.13 Da.
Emzeltrectinib (CAS: 2223678-97-3) is a potent tyrosine kinase inhibitor (TKI) with antineoplastic activity. It is classified under c-MET and is also known as 安泽曲替尼. Molecular formula: C17H15F3N6O; molecular weight: 376.34. Solubility: DMSO 100 mg/mL (265.72 mM). Appearance: Off-white to light yellow solid powder. For research use only. |
| Molecular Formula |
C17H15F3N6O
|
|---|---|
| Molecular Weight |
376.335812807083
|
| Exact Mass |
376.125
|
| Elemental Analysis |
C, 54.26; H, 4.02; F, 15.14; N, 22.33; O, 4.25
|
| CAS # |
2223678-97-3
|
| PubChem CID |
134480550
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
571
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C12=C(C(N)=O)C(N)=NN1C=CC(N1C[C@@H](F)C[C@@H]1C1=CC(F)=CC=C1F)=N2
|
| InChi Key |
YFTARXQOKASKBW-JOYOIKCWSA-N
|
| InChi Code |
InChI=1S/C17H15F3N6O/c18-8-1-2-11(20)10(5-8)12-6-9(19)7-25(12)13-3-4-26-17(23-13)14(16(22)27)15(21)24-26/h1-5,9,12H,6-7H2,(H2,21,24)(H2,22,27)/t9-,12+/m0/s1
|
| Chemical Name |
2-amino-5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
|
| Synonyms |
Emzeltrectinib; 2223678-97-3; 2-amino-5-[(2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-amino-5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; emzeltrectinib [INN];
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (265.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6572 mL | 13.2859 mL | 26.5717 mL | |
| 5 mM | 0.5314 mL | 2.6572 mL | 5.3143 mL | |
| 10 mM | 0.2657 mL | 1.3286 mL | 2.6572 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
